
Agenus Inc. (&#34;Agenus&#34;) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16,

<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Agenus Inc.</b> ("Agenus") (Nasdaq: <b xmlns="http://www.w3.org/1999/xhtml">AGEN</b>), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Agenus</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54438906&amp;newsitemid=20260304473547&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=1&amp;md5=f86a712caaf86fd738d82b34a47d7a71" shape="rect">www.agenusbio.com</a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Botensilimab (BOT)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54438906&amp;newsitemid=20260304473547&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=a0326704004066f21ab3030f7759a583" shape="rect">www.clinicaltrials.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Balstilimab (BAL)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#34;may,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;forecasts,&#34; &#34;estimates,&#34; &#34;will,&#34; "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Source: Agenus Bio</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260304473547r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260304473547/en/" rel="nofollow">https://www.businesswire.com/news/home/20260304473547/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Investors : 917-362-1370 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@agenusbio.com" shape="rect">investor@agenusbio.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: 781-674-4422 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:communications@agenusbio.com" shape="rect">communications@agenusbio.com</a>

</p>

AGEN

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Agenus to announce Q4 results and key strategic plans in March

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Agenus Inc. (&amp;#34;Agenus&amp;#34;) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Agenus Inc. is set to release its Q4 and year-end 2025 financial results before the market opens on March 16, 2026. The upcoming stakeholder webcast will provide updates on the botensilimab and balstilimab clinical programs, which could influence investor sentiment significantly.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Agenus will release Q4 and 2025 results on March 16, 2026.</li><li>Agenus to host a stakeholder briefing to discuss strategic plans in March.</li><li>Clinical trials for botensilimab and balstilimab involve over 2,100 patients.</li><li>Botensilimab targets &#039;cold&#039; tumors, enhancing immune responses in patients.</li><li>Balstilimab has shown favorable tolerability in various tumor types.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>MiNK Therapeutics (MNKT)</strong>: Collaborates with Agenus in developing adoptive cell therapies.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This fits the &#039;Corporate Developments&#039; category as it concerns upcoming earnings and strategic communications. Such updates can significantly influence market sentiments and valuations through perceived changes in the company&#039;s trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming Q4 financial results could affect AGEN&#039;s stock performance.</li><li>Stakeholder webcast may reveal key strategic insights, impacting investor confidence.</li><li>Positive data from botensilimab or balstilimab trials could drive stock price up.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q4 and year-end 2025 results to be released on March 16, 2026.</li><li>Over 1,200 patients treated with botensilimab and/or balstilimab in trials.</li><li>Balstilimab has been evaluated in over 900 patients.</li><li>Agenus focuses on combining immunotherapies to improve cancer treatment.</li><li>Both programs target various late-line metastatic cancers.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider AGEN for potential gains ahead of the March results release.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Agenus Inc.</b> ("Agenus") (Nasdaq: <b xmlns="http://www.w3.org/1999/xhtml">AGEN</b>), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Agenus</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54438906&amp;newsitemid=20260304473547&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=1&amp;md5=f86a712caaf86fd738d82b34a47d7a71" shape="rect">www.agenusbio.com</a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Botensilimab (BOT)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54438906&amp;newsitemid=20260304473547&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=a0326704004066f21ab3030f7759a583" shape="rect">www.clinicaltrials.gov</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Balstilimab (BAL)</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#34;may,&#34; &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;forecasts,&#34; &#34;estimates,&#34; &#34;will,&#34; "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Source: Agenus Bio</b>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260304473547r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260304473547/en/" rel="nofollow">https://www.businesswire.com/news/home/20260304473547/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Investors : 917-362-1370 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@agenusbio.com" shape="rect">investor@agenusbio.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>Media: 781-674-4422 &#x7C; <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:communications@agenusbio.com" shape="rect">communications@agenusbio.com</a>

</p>

Agenus Inc. is set to release its Q4 and year-end 2025 financial results before the market opens on March 16, 2026. The upcoming stakeholder webcast will provide updates on the botensilimab and balstilimab clinical programs, which could influence investor sentiment significantly.

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News